Evidence map›Paper›PMID 24457912›Full record

ArticleBritish journal of cancer2014

FGFR2 amplification has prognostic significance in gastric cancer: results from a large international multicentre study.

X Su, P Zhan, P R Gavine, S Morgan, C Womack, X Ni, D Shen, Y-J Bang, S-A Im, W Ho Kim and 3 more

Registry-linked trialOpen access · hybridAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of cancer, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05019794 (A Phase IIa of Infigratinib in Subjects With Locally Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma With FGFR2 Amplification or Other Advanced Solid Tumors With Other FGFR Alterations), which is not on this map. Cited by 118 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
118citing papers in PubMed, 1 pooled it
11.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05019794 phase2unknown statusnot on this mapstarted 2020, after this paper: background citation

A Phase IIa of Infigratinib in Subjects With Locally Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma With FGFR2 Amplification or Other Advanced Solid Tumors With Other FGFR Alterations

TypeinterventionalSponsorLianBio LLCRan2020 to 2023Enrolled80ConditionsGastric Cancer, Gastroesophageal Junction Adenocarcinoma, Solid TumorArmsInfigratinib
3 · Its place in the literature

Who cites it

118 citing papers in PubMed, 1 synthesis or guideline pooled it, 185 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. FGFR2 amplification and fusion identified by NGS align with FGFR2b overexpression.Virchows Archiv : an international journal of pathology · 2026
    Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Review
  20. Review

58 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 3 countries.

X SuAstraZeneca Asia & Emerging Markets, Innovative Medicines, Shanghai, China.
P ZhanAstraZeneca Asia & Emerging Markets, Innovative Medicines, Shanghai, China.
P R GavineAstraZeneca Asia & Emerging Markets, Innovative Medicines, Shanghai, China.
S MorganAstraZeneca, Oncology Innovative Medicines, Alderley Park, Macclesfield, UK.
C WomackAstraZeneca, Oncology Innovative Medicines, Alderley Park, Macclesfield, UK.
X NiDepartment of General Surgery, Renji Hospital, School of Medicine, Jiaotong University, Shanghai, China.
D ShenDepartment of General Surgery, Renji Hospital, School of Medicine, Jiaotong University, Shanghai, China.
Y-J Bang1] Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea [2] Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea.
S-A Im1] Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea [2] Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea.
W Ho Kim1] Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea [2] Department of Pathology, Seoul National University Hospital, Seoul, Korea.
E-J Jung1] Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea [2] Department of Pathology, Seoul National University Hospital, Seoul, Korea.
H I GrabschLeeds Institute of Cancer and Pathology, University of Leeds, Leeds, UK.
E KilgourAstraZeneca, Oncology Innovative Medicines, Alderley Park, Macclesfield, UK.
Seoul National University · KRAstraZeneca (United Kingdom) · GBShanghai Innovative Research Center of Traditional Chinese Medicine · CNRenji Hospital · CNUniversity of Leeds · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn preclinical gastric cancer (GC) models, FGFR2 amplification was associated with increased tumour cell proliferation and survival, and drugs targeting this pathway are now in clinical trials.

methodsFGFR2 FISH was performed on 961 GCs from the United Kingdom, China and Korea, and the relationship with clinicopathological data and overlap with HER2 amplification were analysed.

resultsThe prevalence of FGFR2 amplification was similar between the three cohorts (UK 7.4%, China 4.6% and Korea 4.2%), and intratumoral heterogeneity was observed in 24% of FGFR2 amplified cases. FGFR2 amplification was associated with lymph node metastases (P<0.0001). FGFR2 amplification and polysomy were associated with poor overall survival (OS) in the Korean (OS: 1.83 vs 6.17 years, P=0.0073) and UK (OS: 0.45 vs 1.9 years, P<0.0001) cohorts, and FGFR2 amplification was an independent marker of poor survival in the UK cohort (P=0.0002). Co-amplification of FGFR2 and HER2 was rare, and when high-level amplifications did co-occur these were detected in distinct areas of the tumour.

conclusionA similar incidence of FGFR2 amplification was found in Asian and UK GCs and was associated with lymphatic invasion and poor prognosis. This study also shows that HER2 and FGFR2 amplifications are mostly exclusive.

Indexed as

Gene AmplificationGene Expression Regulation, NeoplasticAdolescentAdultAgedAged, 80 and overBiomarkers, TumorChinaCohort StudiesErb-b2 Receptor Tyrosine KinasesFemaleHumansIn Situ Hybridization, FluorescenceLymphatic MetastasisMaleMiddle AgedBiomarkers, TumorERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesFGFR2 protein, humanReceptor, Fibroblast Growth Factor, Type 2

Identifiers

PMID24457912
PMCPMC3929881
OpenAlexW2005792607

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.